ClinicalTrials.gg
RecruitingNCT06696755Updated Aug 14, 2026

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

A Phase 2 interventional study of Icalcaprant and Placebo for Icalcaprant in Bipolar I Disorder and Bipolar II Disorder, sponsored by AbbVie. Recruiting at 33 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Bipolar Disorder by AbbVie — 2 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · AbbVie.

Planned enrollment
7th of 11
195 · median 234
Started
2026
with 1 other
Phase 2
6 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Bipolar Disorder by AbbVie, this one is the 7th largest by planned enrollment, is one of 2 that started in 2026, is one of 6 in phase 2, and was the 10th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 11 studies in Bipolar Disorder by AbbVie are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Bipolar Disorder by AbbVie, or all of them as a file.
02

Study summary

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. This study will assess how safe and effective Icalcaprant is in treating adult participants with bipolar I or II disorder.

Icalcaprant is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Participants are placed in 1 of 3 groups, called treatment arms. There is a 1 in 3 chance that a participant will be assigned to a placebo. Around 195 adult participants with bipolar I or II disorder will be enrolled in approximately 35 sites across the United States of America.

Participants will receive oral capsules of Icalcaprant or matching placebo once daily for 6 weeks, with a 4-week safety follow-up period.

There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Bipolar I Disorder
  • Bipolar II Disorder

Browse trials for

Keywords

  • Bipolar I Disorder
  • Bipolar II Disorder
  • Bipolar Disorder
  • lcalcaprant
  • ABBV-1354
  • CVL-354
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of bipolar I or II according to the without psychotic features, confirmed by the MINI 7.0.2, and currently experiencing an MDE beginning at least 4 weeks prior to consent and not exceeding 12 months prior to Screening.
  • (BMI) is >= 18.0 to ≤\<= 35.0 kg/m\^2.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead .
  • CGI-S-BP score of ≥ 4 for depression and overall bipolar illness at screening (Visit 1) and baseline (Visit 2).
  • YMRS total score \<= 12 at screening (Visit 1) and baseline (Visit 2).
  • Participants on treatment with a single mood stabilizer (lithium, valproate, or lamotrigine), maintained at a stable dose for >= 28 days prior to screening. Current mood stabilizer dose must remain unchanged for the duration of the study.
  • If taking lithium or valproate, participant must have a therapeutic blood level at screening of lithium (0.4 - 1.2 mg/dL) or valproate (50 - 125 mg/dL).
  • If taking lamotrigine, participant should be taking a dose within the FDA accepted range (50-400 mg/day, target dose is 200 mg/day) and investigator clinical judgment determines that the dose the participant is taking is likely to prevent onset of mood episodes.

Exclusion criteria

Exclusion Criteria:

  • History of an allergic reaction or significant sensitivity to constituents of the study drug (and its ) and/or other products in the same class.
  • History of or active medical conditions(s) that might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the subject's well-being. This includes any unstable condition, history or evidence of (other than treated basal or squamous cell carcinoma), or any significant hematologic, endocrine, cardiovascular, respiratory, renal, hepatic, gastrointestinal, or neurological disorder (if there is a history of such disease but the condition has been stable for more than 1 year, does not require treatment with prohibited medications, and is judged by the investigator not to interfere with the participant's participation in the study, the participant may be included in the study).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
195 participants (estimated)

Study arms

  • Experimental
    Group 1: Icalcaprant Dose A

    Participants will receive oral Icalcaprant dose A once daily for 6 weeks and followed for 4 weeks.

    Drug: Icalcaprant

  • Experimental
    Group 2: Icalcaprant Dose B

    Participants will receive oral Icalcaprant dose B once daily for 6 weeks and followed for 4 weeks.

    Drug: Icalcaprant

  • Placebo comparator
    Group 3: Placebo for Icalcaprant

    Participants will receive oral placebo for Icalcaprant daily for 6 weeks and followed for 4 weeks.

    Drug: Placebo for Icalcaprant

Interventions

  • Oral Capsules

    Also known as: ABBV-1354, CVL-354

  • DrugPlacebo for Icalcaprant

    Oral Capsules

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) total score

    MADRS is a depression rating scale consisting of 10 items representing the core symptoms of depressive illness, each rated 0 (no symptom) to 6 (severe symptom). Total score ranges from 0 (no depression) to 60 (severely depressed).

    Time frame: Up to approximately Week 6

  2. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study

    Time frame: Up to approximately 10 weeks

Secondary outcomes

  1. Change from Baseline to Week 6 in Clinician Global Impression of Severity - Bipolar Disorder (CGI-S-BP) score

    Clinician Global Impression of Severity - Bipolar Disorder (CGI-S-BP) is a clinician-reported measure of severity of mania, depression, and overall bipolar disorder. Clinicians are asked to consider their total clinical experience with bipolar subjects and assess how severely ill has the participant been during the past 7 days. Response options range from 'Normal, not ill' to 'Very severely ill'.

    Time frame: Up to approximately Week 6

07

Study locations

33 of 33 sites recruiting
  • University of Alabama - Huntsville Regional Medical Campus /ID# 272951
    Huntsville, Alabama 35801, United States
    Recruiting
  • Chandler Clinical Research Trials /ID# 274500
    Chandler, Arizona 85224, United States
    Recruiting
  • Del Sol Research Management - East Tanque Verde Road - Tucson /ID# 279767
    Tucson, Arizona 85715, United States
    Recruiting
  • Sanro Clinical Research Group /ID# 279462
    Bryant, Arkansas 72022, United States
    Recruiting
  • Advanced Research Center /ID# 272828
    Anaheim, California 92805, United States
    Recruiting
  • Collaborative Neuroscience Research - Garden Grove /ID# 271917
    Garden Grove, California 92845, United States
    Recruiting
  • Catalina Research Institute /ID# 272831
    Montclair, California 91763, United States
    Recruiting
  • Excell Research /ID# 272854
    Oceanside, California 92056, United States
    Recruiting
  • Pacific Neuropsychiatric Specialists - Orange /ID# 273118
    Orange, California 92868, United States
    Recruiting
  • Schuster Medical Research Institute /ID# 272848
    Sherman Oaks, California 91403, United States
    Recruiting
  • Sarkis Clinical Trials- Gainesville /ID# 272861
    Gainesville, Florida 32607, United States
    Recruiting
  • CenExel Hollywood FL /ID# 273101
    Hollywood, Florida 33024, United States
    Recruiting
  • Accel Research Sites Network - St. Pete /ID# 272962
    Largo, Florida 33777, United States
    Recruiting
  • Apg Research /ID# 272925
    Orlando, Florida 32803, United States
    Recruiting
  • Combined Research Orlando /ID# 279458
    Orlando, Florida 32814, United States
    Recruiting
  • Clinical Research Center Of Florida /ID# 278790
    Pompano Beach, Florida 33060, United States
    Recruiting
  • St. Johns Center for Clinical Research - Saint Augustine Location /ID# 279465
    Saint Augustine, Florida 32086, United States
    Recruiting
  • Neuroscience Institute - West Palm Beach /ID# 272922
    West Palm Beach, Florida 33407, United States
    Recruiting
  • Georgia Psychiatric Consultants and Advanced Discovery Research /ID# 279438
    Atlanta, Georgia 30318, United States
    Recruiting
  • Pillar Clinical Research - Chicago /ID# 272823
    Chicago, Illinois 60641, United States
    Recruiting
    • Site Coordinator · Contact2245347332
  • Amr Conventions Research /ID# 272867
    Warrenville, Illinois 60555, United States
    Recruiting
  • Saint Charles Psychiatric Associates /ID# 279239
    Saint Charles, Missouri 63304, United States
    Recruiting
  • Manhattan Behavioral Medicine /ID# 279769
    New York, New York 10036, United States
    Recruiting
  • University Of Cincinnati Medical Center /ID# 274160
    Cincinnati, Ohio 45219, United States
    Recruiting
  • The Ohio State University /ID# 272954
    Columbus, Ohio 43210, United States
    Recruiting
  • Sooner Clinical Research /ID# 272856
    Oklahoma City, Oklahoma 73116, United States
    Recruiting
  • Community Clinical Research - Cross Park Drive /ID# 272940
    Austin, Texas 78754, United States
    Recruiting
  • Elixia - Houston /ID# 279200
    Houston, Texas 77007, United States
    Recruiting
  • Mind Matters Psychiatry /ID# 273536
    Missouri City, Texas 77459-5204, United States
    Recruiting
  • Pillar Clinical Research - Richardson /ID# 272821
    Richardson, Texas 75080, United States
    Recruiting
  • Family Psychiatry Of The Woodlands /ID# 275177
    The Woodlands, Texas 77381, United States
    Recruiting
  • Northwest Clinical Research Center /ID# 272847
    Bellevue, Washington 98007, United States
    Recruiting
  • Core Clinical Research /ID# 272955
    Everett, Washington 98201, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2027, 21 months after the start.

Of 56 phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 20, 2024
StartActual
Feb 3, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06696755
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 20, 2024
Start date
Feb 3, 2026
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icalcaprant

Start the discussion